Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Bioshares Biotech Summit 2022
19 slides from Radiopharm Theranostics's conference presentation, May 12, 2022
Slide 1: Bioshares Summit 2022
For personal use only BIOSHARES SUMMIT 2022 Riccardo Canevari CEO, Radiopharm Theranostics Ltd
Slide 2: Disclaimer
DISCLAIMER The information in this presentation does not constitute personal Certain statements contained in this presentation, including, without For personal use only investment advice. The presentation is not intended to be comprehensive or limitation, statements containing the words “believes,”
Slide 3: What is the new frontier in oncology? And the next $40B platform?
WHAT IS THE NEW FRONTIER IN ONCOLOGY? AND THE NEXT $40B PLATFORM? For personal use only WORLDWIDE ONCOLOGY MARKET in 2025 = ~290B$; CAGR 5y (2020-2025) = 13% CHEMO and TARGETED Therapies = ~190 B$; CAGR 5y (2020-2025) = 9% CAGR 22% 90 85 80 I/O Therapies 70 60 50 40 30 CAGR 66% 20 14 10 0 I/O Therap
Slide 4: Radiopharmaceutical therapies has the potential to transform the treatment paradigm
RADIOPHARMACEUTICAL THERAPIES HAS THE POTENTIAL TO TRANSFORM THE TREATMENT PARADIGM For personal use only WORLDWIDE ONCOLOGY MARKET in 2025 = ~290B$; CAGR 5y (2020-2025) = 13% CHEMO and TARGETED Therapies = ~190 B$; CAGR 5y (2020-2025) = 9% CAGR 22% 90 85 80 I/O Therapies 70 60 50 40 30 CAGR 66% 20
Slide 5: Exciting scientific evidence is changing the treatment paradigm
EXCITING SCIENTIFIC EVIDENCE IS CHANGING THE TREATMENT PARADIGM For personal use only R AD I O P H A R M T H E R A N O S T I C S L T D 2 0 2 2 C O N F I D E N T I AL | 5
Slide 6: Increasing number of bolt on acquisitions in radiopharmaceuticals
INCREASING NUMBER OF BOLT ON ACQUISITIONS IN RADIOPHARMACEUTICALS For personal use only R AD I O P H A R M T H E R A N O S T I C S L T D 2 0 2 2 C O N F I D E N T I AL | 6
Slide 7: Only prostate and NET benefit from radiopharmaceuticals, only three big pharma active
ONLY PROSTATE AND NET BENEFIT FROM RADIOPHARMACEUTICALS, ONLY THREE BIG PHARMA ARE ACTIVE IN THE SECTOR For personal use only (2013) (2022) 3 approved therapies in 3 Big Pharma out of top 20 oncology segments top 20 Pharma Companies Combined analysts’ peak sales consensus for Xofigo, Lutathera, Pluv
Slide 8: The role of Radiopharm Theranostics
THE ROLE OF RADIOPHARM THERANOSTICS For personal use only Founded: February 2021 Where: Australia 1st Capital Raise: $20m Jul 2021 2nd Capital Raise: $50m IPO Nov 2021 ASX Ticker: RAD AMBITION: become the recognized Leader in fighting cancer, through innovative radiopharmaceutical therapies, in area
Slide 9: Executive Leadership Team
EXECUTIVE LEADERSHIP TEAM For personal use only RICCARDO PROF DAVID DR THOM PAUL CANEVARI MOZLEY TULIP HOPPER MANAGING DIRECTOR / CEO CHIEF MEDICAL OFFICER CHIEF TECHNICAL OFFICER EXECUTIVE CHAIRMAN Riccardo was most recently Chief David was most recently at Cornell Thom has spent more than 25 Paul
Slide 10: Five distinct and well differentiated platforms
FIVE DISTINCT & WELL DIFFERENTIATED PLATFORMS ONE OF THE DEEPEST PIPELINE OF RADIOPHARMACEUTICAL THERAPIES For personal use only Nano-mAbs Avb6 Integrin PSA-mAb Pivalate DUNP19 80 patients dosed 43 patients dosed 44 patients dosed Single chain Peptide molecule Monoclonal Small molecule Monoclonal mo
Slide 11: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD Pivalate AVβ6 Integrin Nano-mAbs PSA-mAb For personal use only DUNP 19 PROF ERIC DR JOHANNES DR HONG PROF SARA DR DAVID ABOAGYE NOTNI HOI TING HURVITZ ULMERT Eric Aboagye is a Professor of Dr Notni is an acknowledged authority Dr Hong obtained his Sara A Hurvitz, MD, is Pro
Slide 12: Build a leadership position targeting key pathways with multiple innovative molecules
BUILD A LEADERSHIP POSITION TARGETING KEY PATHWAYS WITH MULTIPLE INNOVATIVE MOLECULES Cancer type New Cases RAD Pipeline Target / Moa For personal use only 1 Breast 280.000 HER2 / TROP2 2 Prostate 248.000 KLK3 3 Lung 235.000 PDL1 4 Colorectal 149.000 5 Melanoma 106.000 6 Bladder 83.000 7 Kidney 76.0
Slide 13: Scientific winning proposition: combining the right molecule with the right isotope
SCIENTIFIC WINNING PROPOSITION: COMBINING THE RIGHT MOLECULE WITH THE RIGHT ISOTOPE IN THE RIGHT DISEASE AREA * Deal signed ** Deal to be signed in the next 90 days For personal use only Unique molecules Therapeutic Isotopes 1 HER2 nanobody 2 PDL1 nanobody 1 Ac225* α emitter TROP2 2 Re188* β emitter
Slide 14: Development plan
NEXT 18 MONTH - DEVELOPMENT PLAN 1 trial readout + 4 new trial start 6 trial readout + 6 new trial start For personal use only 2022 2023 4 “First to market” or “Best in class” potential H1 H2 H1 H2 8 IMAGING Phase 2a readout Phase 2a Phase 2a Phase 2a Phase 1 THERAPEUTICS FPIA Brain Mets Phase 1 FPI
Slide 15: Development plan
NEXT 18 MONTH - DEVELOPMENT PLAN 1 trial readout + 4 new trial start 6 trial readout + 6 new trial start For personal use only 2022 2023 4 “First to market” or “Best in class” potential H1 H2 H1 H2 8 IMAGING Phase 2a readout Phase 2a Phase 2a Phase 2a Phase 1 THERAPEUTICS FPIA Brain Mets Phase 1 FPI
Slide 16: Our most recent acquisition: DUNP19
OUR MOST RECENT ACQUISITION DUNP19: Humanized mAb targeting LRRC15 expression Unique MoA and very fast internalization For personal use only R AD I O P H A R M T H E R A N O S T I C S L T D 2 0 2 2 C O N F I D E N T I AL | 1 6
Slide 17: LRRC15 is highly present in multiple tumor types
LRRC15 IS HIGHLY PRESENT IN MULTIPLE TUMOR TYPES, WITH VERY LIMITED EXPRESSION IN HEALTHY TISSUES 1. Adrenocortical carcinoma For personal use only 2. Bladder Urothelial Carcinoma 3. Breast invasive carcinoma 4. Cervical/endocervical carcinoma 5. Cholangio carcinoma 6. Colon adenocarcinoma 7. Lympho
Slide 18: In a fast-growing market, with one of the deepest pipelines
IN A FAST-GROWING MARKET, WITH ONE OF THE DEEPEST PIPELINES For personal use only Radiopharmaceutical Radiopharmaceutical Radiopharmaceuticals Therapies has the Therapies can play a Therapies experiencing a potential to be the new significant role in areas high level of investor frontier in ~290B$ o
Slide 19: Contact Us
For personal use only CONTACT US Riccardo Canevari Paul Hopper CEO & MANAGING DIRECTOR Executive Chairman Radiopharm Theranostics Limited Radiopharm Theranostics Limited T +1 862 309 0293 T +61 406 671 515 E rc@radiopharmtheranostic.com E paulhopper@lifescienceportfolio.com W www.radiopharmtheranost
Radiopharm Theranostics — Bioshares Biotech Summit 2022 on 6ix